Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01534689 |
Recruitment Status :
Completed
First Posted : February 17, 2012
Results First Posted : December 11, 2015
Last Update Posted : December 11, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Onychomycosis | Device: Erchonia FX-405™ Laser | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 105 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Evaluation of the Effect of the Erchonia FX-405™ on Treating Toenail Onychomycosis Clinical Study |
Study Start Date : | April 2011 |
Actual Primary Completion Date : | April 2012 |
Actual Study Completion Date : | April 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: Erchonia FX-405™ Laser
The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
|
Device: Erchonia FX-405™ Laser
The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time. |
- Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail [ Time Frame: 12 weeks ]
Millimeter (mm) of clear nail from the base of the lunula was measured from digital photographs of the toenail using a computer program. Change in mm of clear nail bed was calculated as the difference in mm of clear nail bed from baseline measurement to the measurement at 3 months post-procedure administration. The percent (%) of increase in clear nail from baseline was calculated from there. An increase in mm or percent of clear nail between the two measurement points indicates the toenail onychomycosis has improved and is positive for study success. A decrease in mm or percent of clear nail between the two measurement points indicates the toenail onychomycosis has worsened and is negative for study success.
Individual toenail success criteria was defined as 25 percent (%) or more increase in clear nail growth at 3 months post-procedure relative to baseline. Overall study success criteria was defined as 60% or more of treated toenails meeting the individual success criteria.
- Change in Millimeter (mm) of Clear Nail Bed [ Time Frame: 12 weeks ]Millimeter (mm) of clear nail from the base of the toenail lunula was determined from digital photographs of the toenail using a computer program. Change in mm of clear nail bed was calculated as the difference in mm of clear nail bed from baseline measurement to the measurement at 3 months post-procedure administration. An increase in mm of clear nail between the two measurement points indicates that the toenail onychomycosis has improved and is positive for study success. A decrease in mm of clear nail between the two measurement points indicates that the toenail onychomycosis has worsened and is negative for study success.
- Change in Percent (%) of mm Clear Nail [ Time Frame: 12 weeks ]Millimeter (mm) of clear nail from the base of the lunula was measured from digital photographs of the toenail using a computer program. Change in mm of clear nail bed was calculated as the difference in mm of clear nail bed from baseline measurement to the measurement at 3 months post-procedure administration. The percent (%) of increase in clear nail from baseline was calculated from there.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Onychomycosis present in at least one great toenail.
- Disease involvement is at least 25%.
- Subject is willing and able to refrain from employing other (non-study) treatments (traditional or alternative) for his or her toenail onychomycosis throughout study participation.
- Subject is willing and able to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers throughout study participation.
Exclusion Criteria:
- Spikes of disease extending to nail matrix.
- Infection involving lunula, e.g., genetic nail disorders, primentary disorders.
- Less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
- Presence of dermatophytoma (thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed).
- Chronic plantar (moccasin) tinea pedis.
- History of current or past psoriasis of the skin and/or nails.
- Concurrent lichen planus.
- Onychogryphosis.
- Any of the following conditions of the great toenail:
- proximal subungual onychomycosis
- white superficial onychomycosis
- dermatophytoma or "yellow spike/streak"
- exclusively lateral disease
- confounding problems/abnormalities of the great toenail(s).
- Any abnormality that could prevent a normal appearing nail if clearing of infection is achieved.
- Inability for the toenail to become normal in the opinion of the investigator.
- History of multiple repeated failures with previous therapies for onychomycosis.
- Trauma to the affected great toenail(s).
- Use of oral antifungal agents in the past 6 months.
- Use of topical antifungal agents in the past 1 month.
- Prior surgical treatment of the affected great toe(s).
- Cancer and/or treatment of any type of cancer within the last six months.
- Peripheral vascular disease or peripheral circulatory impairment.
- History of uncontrolled diabetes mellitus.
- Known immunodeficiency.
- Known sensitivity, or contraindication, to light therapy.
- Pregnant, breast feeding, or planning pregnancy prior to the end of study participation.
- Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
- Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
- Involvement in litigation and/or receiving disability benefits related in any way to the parameters of the study.
- Participation in a clinical study or other type of research in the past 30 days.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01534689
United States, Arizona | |
Arizona Institute of Footcare Physicians | |
Mesa, Arizona, United States, 85204 |
Principal Investigator: | Kerry Zang, DPM |
Responsible Party: | Erchonia Corporation |
ClinicalTrials.gov Identifier: | NCT01534689 |
Other Study ID Numbers: |
EC_TF_001 |
First Posted: | February 17, 2012 Key Record Dates |
Results First Posted: | December 11, 2015 |
Last Update Posted: | December 11, 2015 |
Last Verified: | November 2015 |
Onychomycosis Tinea Dermatomycoses Skin Diseases, Infectious |
Infection Mycoses Nail Diseases Skin Diseases |